AI-generated analysis. Always verify with the original filing.
Plus Therapeutics, Inc. implemented a 1-for-25 reverse stock split effective April 2, 2026, reducing outstanding common shares from approximately 171,550,698 to 6,862,027 to meet Nasdaq's $1.00 minimum bid price requirement.
Event Type
Disclosure
Mandatory
Variant
8-K
Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defi
of this Current Report on Form 8-K is incorporated by reference herein. ## Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. A
Other Events. On March 31, 2026, the Company issued a press release relating to the matters described in Item 5.03 above. A copy of the press release is attache
Financial Statements and Exhibits. (d) Exhibits.: Exhibit Number | Col3: Description (d) Exhibits.: 3.1 | Col3: Certificate of Amendment to the Amended and Rest